Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
作者信息
Brentjens Renier, Yeh Raymond, Bernal Yvette, Riviere Isabelle, Sadelain Michel
出版信息
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
Abstract
摘要
相似文献
1
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.采用基因靶向自体T细胞治疗慢性淋巴细胞白血病：一项I期临床试验中意外不良事件的病例报告
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
2
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.新型含人源可变区的抗 CD19 嵌合抗原受体的功能受铰链和跨膜结构域影响。
Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.
3
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.自体 CD19 靶向 CAR T 细胞治疗初始嘌呤类似物为基础治疗后 CLL 患者的残留病灶。
Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15.
4
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.依鲁替尼治疗失败后，用CD19特异性嵌合抗原受体修饰的T细胞治疗慢性淋巴细胞白血病的持久分子缓解。
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
5
6
CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病及慢性淋巴细胞白血病的潜力
Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4.
7
Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.嵌合抗原受体T细胞疗法治疗慢性淋巴细胞白血病：一项叙述性综述
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):852-856. doi: 10.1016/j.clml.2017.07.007. Epub 2017 Jul 21.
8
Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.四价双特异性CD19xCD3重组抗体构建体和CD28共刺激对慢性淋巴细胞白血病患者自体T细胞裂解恶性B细胞的影响。
Int J Cancer. 2004 Nov 10;112(3):509-18. doi: 10.1002/ijc.20417.
9
Chasing cancer with chimeric antigen receptor therapy.用嵌合抗原受体疗法治疗癌症。
Immunotherapy. 2012 Apr;4(4):365-7. doi: 10.2217/imt.12.16.
10
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.重定向针对人免疫球蛋白κ轻链的T淋巴细胞可有效杀伤成熟B淋巴细胞衍生的恶性细胞。
Blood. 2006 Dec 1;108(12):3890-7. doi: 10.1182/blood-2006-04-017061. Epub 2006 Aug 22.
引用本文的文献
1
Nanotechnology for immuno-oncology.免疫肿瘤学的纳米技术
Nat Cancer. 2025 Aug 7. doi: 10.1038/s43018-025-01025-x.
2
The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment.嵌合抗原受体T细胞疗法与急性淋巴细胞白血病治疗中神经并发症之间的斗争
Curr Issues Mol Biol. 2025 May 21;47(5):381. doi: 10.3390/cimb47050381.
3
Targeted Cellular Treatment of Systemic Lupus Erythematosus.系统性红斑狼疮的靶向细胞治疗
Cells. 2025 Jan 31;14(3):210. doi: 10.3390/cells14030210.
4
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.嵌合抗原受体T细胞（CAR-T）疗法监测的进展与挑战：血液系统恶性肿瘤中参数和标志物的综合综述
Cancers (Basel). 2024 Sep 29;16(19):3339. doi: 10.3390/cancers16193339.
5
CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.嵌合抗原受体 T 细胞疗法治疗系统性红斑狼疮：全面综述。
Int J Mol Sci. 2024 Sep 29;25(19):10511. doi: 10.3390/ijms251910511.
6
CD8 T Cell Biology in Cytokine Storm Syndromes.细胞因子风暴综合征中的 CD8 T 细胞生物学。
Adv Exp Med Biol. 2024;1448:129-144. doi: 10.1007/978-3-031-59815-9_10.
7
mRNA vaccine development and applications: A special focus on tumors (Review).mRNA 疫苗的开发与应用：特别关注肿瘤（综述）。
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5669. Epub 2024 Jul 12.
8
Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T-ALL-iPSC in vivo.评估源自T-ALL-iPSC的肿瘤抗原致敏的细胞毒性T细胞疗法在体内的安全性和有效性。
Cancer Innov. 2023 Oct 19;3(1):e95. doi: 10.1002/cai2.95. eCollection 2024 Feb.
9
CAR-T cell-derived exosomes: a new perspective for cancer therapy.CAR-T 细胞衍生的外泌体：癌症治疗的新视角。
Stem Cell Res Ther. 2024 Jun 18;15(1):174. doi: 10.1186/s13287-024-03783-4.
10
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.自调节 CAR-T 细胞调节过继性 T 细胞疗法中的细胞因子释放综合征。
J Exp Med. 2024 Jun 3;221(6). doi: 10.1084/jem.20221988. Epub 2024 Apr 12.
本文引用的文献
1
The promise and potential pitfalls of chimeric antigen receptors.嵌合抗原受体的前景与潜在风险。
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.
2
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.用于自体过继性细胞治疗的靶向CD19抗原的生物功能性T细胞的生产验证。
J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.
3
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.基因靶向T细胞根除系统性急性淋巴细胞白血病异种移植瘤。
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. doi: 10.1158/1078-0432.CCR-07-0674. Epub 2007 Sep 12.
4
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.通过由CD80和白细胞介素-15共同刺激的基因靶向人类T淋巴细胞根除系统性B细胞肿瘤。
Nat Med. 2003 Mar;9(3):279-86. doi: 10.1038/nm827. Epub 2003 Feb 10.
5
Targeting tumours with genetically enhanced T lymphocytes.利用基因增强的T淋巴细胞靶向肿瘤。
Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971.
6
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.由单一嵌合型TCRζ/CD28受体介导的人T淋巴细胞细胞毒性和增殖
Nat Biotechnol. 2002 Jan;20(1):70-5. doi: 10.1038/nbt0102-70.
Zotero 插件